Your browser version may not work well with NCBI's Web applications. More information here...
1: Acta Paediatr Scand Suppl. 1987;337:147-52.Links

Clinical experience with Genotropin worldwide: an update March 1987.

Gunnarsson R, Wilton P.

Medical Department, KabiVitrum Peptide Hormones, Stockholm, Sweden.

The efficacy and safety of Genotropin (recombinant somatropin, KabiVitrum AB, Sweden) was analysed in 199 children with hGH deficiency, comprising a combined series of four current multicentre trials. Stimulation of linear growth from pretreatment height velocities of 3-4 cm/year to about 10 cm/year was observed after 6 and 9 months of treatment. Statistical analysis revealed significantly greater height velocities (by 2-3 cm/year) when the weekly dose of the hormone was given in 6-7 injections rather than in 3 injections. Immunogenicity seems to be very low, with only about 2% of the children having detectable antibodies during treatment.

PMID: 3324636 [PubMed - indexed for MEDLINE]